[{"id":"e48114c4-2c36-41f9-bc27-1f9242719dc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284488","created_at":"2021-01-18T20:47:55.803Z","updated_at":"2024-07-02T16:35:32.408Z","phase":"Phase 1/2","brief_title":"Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors","source_id_and_acronym":"NCT04284488","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • dasminapant (APG-1387)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 04/10/2020","start_date":" 04/10/2020","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-10-20"}]